Drugs / CSL311
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04082754 | Nov 2019 → Nov 2023 | asthma | CSL Behring | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSL311 | “A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers” NCT04082754 ↗ |
| Action | Inhibit | “Human beta common receptor antagonist monoclonal antibody” NCT04082754 ↗ |
| Modality | Monoclonal antibody | “Human beta common receptor antagonist monoclonal antibody” NCT04082754 ↗ |
| Route | Intravenous | “Human beta common receptor antagonist monoclonal antibody administered intravenously at a Single Ascending Dose (SAD)” NCT04082754 ↗ |